clinical trial · NCT06990269
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
ADARx Pharmaceuticals, Inc.·phase2·recruiting·n = 240
Geographic Atrophy Secondary to Age-related Macular DegenerationADX-038Placebo
brief summary
Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assessed.
started
Nov 10, 2025
primary completion
Feb 28, 2030
completion
Aug 30, 2030
last updated
Apr 22, 2026
official title
A Phase 2, Randomized, Masked, Placebo-Controlled Study of Subcutaneously Administered ADX-038 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol